Last reviewed · How we verify
QM1114-DP
QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin.
QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin. Used for Acne vulgaris.
At a glance
| Generic name | QM1114-DP |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | topical retinoid |
| Target | retinoic acid receptor |
| Modality | Biologic |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It works by modulating the immune response and reducing inflammation in the skin, which helps to alleviate symptoms of acne and other inflammatory skin conditions.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
Key clinical trials
- Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines (PHASE3)
- Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines (PHASE3)
- A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines (PHASE3)
- Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (PHASE3)
- Treatment of Moderate to Severe Glabellar Lines (PHASE3)
- Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (PHASE3)
- Treatment of Moderate to Severe Lateral Canthal Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QM1114-DP CI brief — competitive landscape report
- QM1114-DP updates RSS · CI watch RSS
- Galderma R&D portfolio CI